In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brookhaven National Laboratory

Division of US Department of Energy
www.bnl.gov

Latest From Brookhaven National Laboratory

Deals Shaping the Medical Industry (12/06)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Deals Shaping the Medical Industry (9/06)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Psimei Pharmaceuticals PLC

Psimei Pharmaceuticals aims to improve the outcome of conventional radiotherapy for cancer patients by applying its Photon Activation Therapy (PAT) and Boron Neutron Capture Therapy (BNCT) technologies. The UK start-up has so far raised one million pounds since it was founded in January 2001.
BioPharmaceutical Europe

State University of New York at Stony Brook

The discoveries of the platelet-inhibiting antibody, ReoPro, and PerioStat, a formulation of doxycycline, put SUNY-Stony Brook on the tech transfer map. It is now working with start-ups, too.
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register